Introduction {#Sec1}
============

Chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality, is characterized by persistent airflow limitation that is usually progressive \[[@CR1]\]. The prevalence of COPD in Japan is reported to be 8.6%, which is comparable to the global prevalence \[[@CR2]\]. In Japan, approximately 5.3 million individuals ≥40 years old and 2.1 million individuals ≥70 years old are estimated to be affected by COPD \[[@CR3]\]. Bronchodilators are recommended as first-line therapy in symptomatic patients with airflow limitation, and are fundamental to the management of stable COPD \[[@CR4], [@CR5]\]. Long-acting muscarinic antagonist (LAMA) and long-acting β~2~-agonist (LABA) combination therapy is recommended if symptoms persist despite treatment with bronchodilator monotherapy \[[@CR5]\]. Fixed-dose combinations (FDCs) of LAMA + LABA can maximize the bronchodilator response without increasing the dose of individual components by LABA-mediated stimulation of β~2~-adrenergic receptors, LAMA-mediated inhibition of acetylcholine action at muscarinic receptors, and signaling cross-talk-induced synergistic bronchodilation effects \[[@CR6], [@CR7]\]. Further, the safety of LAMA + LABA combination therapies and monotherapies is comparable \[[@CR8], [@CR9]\].

Tiotropium/olodaterol FDC is a LAMA + LABA FDC approved for use in many countries, including Japan, the European Union, and the United States. Numerous randomized, double-blind, placebo-controlled, phase III studies (with durations of 6, 12, and 52 weeks), including parallel-group and crossover studies, have shown that treatment with tiotropium/olodaterol FDC (5/5 and/or 2.5/5 µg) significantly improved lung function \[[@CR10]--[@CR12]\], quality of life \[[@CR10], [@CR13]\], and transition dyspnea index \[[@CR13]\] compared with either monotherapy in patients with moderate-to-very severe COPD \[Global Initiative for Chronic Obstructive Lung Disease (GOLD), grades 2--4\]. In particular, in the Japanese subpopulation of replicated phase III studies (TONADO^®^ 1 and 2), tiotropium/olodaterol FDC (5/5 µg) was superior to either monotherapy for lung function and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks, being consistent with results of the overall population \[[@CR14]\].

Also, in several phase III studies, tiotropium/olodaterol FDC showed a significant improvement/reduction in lung hyperinflation \[an increase in inspiratory capacity (IC)\] after 6 or 12 weeks treatment compared with either monotherapy or placebo \[[@CR15], [@CR16]\]. However, no Japanese patients with COPD were included in these studies. Importantly, Japanese patient characteristics such as age, body mass index, smoking habits, maintenance treatment usage, and environmental exposures differ from those of Western patients \[[@CR17], [@CR18]\]. Therefore, the VESUTO^®^ study has been planned to investigate the effect of tiotropium/olodaterol FDC and tiotropium monotherapy on IC as an index of lung hyperinflation in Japanese patients with COPD, because lung hyperinflation is one of the main factors for dyspnea, fatigue, and low exercise capacity \[[@CR19], [@CR20]\]. The 6-min walk distance (6MWD) is a validated measure of exercise capacity and correlates well with IC \[[@CR21]\], responds to interventions with bronchodilators \[[@CR22]\], and predicts morbidity and mortality \[[@CR23]\]. Reduction in hyperinflation (increase in IC) with tiotropium/olodaterol FDC is considered to be associated with improvement in exercise capacity \[[@CR15], [@CR16]\] and possibly in physical activity \[[@CR24]\]. Therefore, it is expected that improvement of symptoms resulting from reduction of hyperinflation will contribute to increasing patients' exercise capacity and their daily activity \[[@CR25]\]. Physical activity levels could be a new therapeutic target for COPD management \[[@CR26]\], because low physical activity is associated with poor prognosis and is the most influential factor affecting all-cause mortality in COPD \[[@CR27], [@CR28]\], ranking as the third most important factor associated with death caused by lifestyle-related diseases in Japan \[[@CR29]\]. Assessment of physical activity in the earliest stages of COPD is associated with better prognosis, as it helps maintain best achievable physical activity \[[@CR27], [@CR28]\]. Nonetheless, Japan is known for taking active measures to improve the health of its population \[[@CR29]\]. Guidelines for the diagnosis and treatment of COPD issued by the Japanese Respiratory Society specifically include improvement in exercise capacity and daily physical activity as one of six treatment goals \[[@CR5]\]. However, its importance has only recently been recognized, and evidence demonstrating the effect of bronchodilators on physical activity is limited \[[@CR30]--[@CR32]\]. Furthermore, there are no randomized interventional studies focused on exercise capacity and physical activity in Japanese patients with COPD. Given that tiotropium is widely used as first-line monotherapy for maintenance management of COPD in Japan, the VESUTO^®^ study has been planned to investigate the efficacy of tiotropium/olodaterol FDC compared to tiotropium monotherapy on exercise capacity (measured by 6MWD) and daily physical activity (measured by a 3-axis accelerometer).

This paper describes the study design of the VESUTO^®^ study (NCT02629965), which is the first, randomized, 2-way crossover, interventional study (2 × 2 crossover study with 90 patients in each sequential group; in total, 180 patients/treatment group) in Japanese patients with COPD.

This study aims to assess the efficacy of tiotropium/olodaterol FDC compared with tiotropium monotherapy on IC as an index of lung hyperinflation in Japanese patients with COPD. In addition, the effect of these bronchodilators on exercise capacity and amount of daily physical activities will also be assessed.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The VESUTO^®^ study is a randomized, double-blind, active-controlled, 2-way crossover clinical study to assess the efficacy of once-daily administration of orally inhaled tiotropium/olodaterol FDC or tiotropium monotherapy on pulmonary function (lung hyperinflation), exercise capacity \[6-min walk test (6MWT)\], and physical activity measured by a 3-axis accelerometer in Japanese patients with COPD (NCT02629965). Patient follow-up in the study includes Visit 0 (informed consent), Visit 1 (screening), Visit 2 (randomization), Visit 3 to Visit 4 (assessment after crossover with 6-week treatment period), and Visit 5 (follow-up) (Fig. [1](#Fig1){ref-type="fig"}). This study protocol was finalized on October 30, 2015 as version 1.0. The study began in February 2016 in Japan.Fig. 1Study design. *6MWT* 6-min walk test, *EOT* end of treatment, *FDC* fixed-dose combination, *IC* inspiratory capacity, *LABA* long-acting β~2~ agonist, *LAMA* long-acting muscarinic antagonist, *PFTs* pulmonary function tests, *V* visit

The study will be carried out in compliance with the protocol, the principles laid down in the Declaration of Helsinki in accordance with the International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), relevant Boehringer Ingelheim Standard Operating Procedures, and the Japanese GCP regulations (Ministry of Health and Welfare Ordinance No. 28, March 27, 1997). The study was initiated only after all required legal documentation had been reviewed and approved by the respective Institutional Review Board and competent authority according to regulations in Japan. The detailed information of each Institutional Review Board is included in Supplementary Table S1. For inclusion, all patients must sign a written informed consent prior to participation in the study, which includes medication washout and restrictions. Standard medical care (prophylactic, diagnostic, and therapeutic procedures) remains the responsibility of the treating physician of the patient. Study data will be collected, analyzed, and published without personal identifiable information. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist is provided in Supplementary Table S2.

Study Population and Setting {#Sec4}
----------------------------

Men or women outpatients, aged ≥40 years with a diagnosis of COPD and stable airway obstruction, will be invited to participate in the study. Patients will be required to perform the 6MWT on several occasions during the study. Patients with any contraindication to exercise as stipulated in the European Respiratory Society (ERS) guidelines \[[@CR33]\], and supported by the American Thoracic Society (ATS)/American College of Chest Physician guidelines will be excluded from participation \[[@CR34]\]. The VESUTO^®^ study has been planned to be conducted mainly at respiratory medicine centers of general clinics and hospitals located in major cities in Japan.

Inclusion and Exclusion Criteria {#Sec5}
--------------------------------

Patients will be required to have a diagnosis of COPD and stable airway obstruction with post-bronchodilator forced expiratory volume in 1 s (FEV~1~)/forced vital capacity (FVC) \<70%, post-bronchodilator FEV~1~ \<80% of predicted normal, and GOLD grade 2--4 at Visit 1. Patients must be current or ex-smokers with a smoking history of \>10 pack-years. Patients must also have a score of ≥1 on the modified Medical Research Council (mMRC) scale, 6MWD \<400 m, and have a breathing discomfort on the modified Borg scale ≥4 measured just after the 6MWT at Visit 2. The criterion of the 6MWD \<400 m is referred to in studies that evaluated the combination therapy of tiotropium and formoterol compared to tiotropium \[[@CR22]\] and the ECLIPSE study which considered the relation of 6MWD with survival rate \[[@CR23]\].

Main exclusion criteria are presence of a significant disease other than COPD; clinically relevant abnormal baseline hematology, blood chemistry, urinalysis, or creatinine more than twice the upper limit of normal; and current documented diagnosis of asthma. The main exclusion criteria are listed in Table [1](#Tab1){ref-type="table"}.Table 1List of exclusion criteria1Patients with a diagnosis ofa. Asthma\
b. Thyrotoxicosis\
c. Paroxysmal tachycardia (\>100 beats per minute)\
d. Life-threatening cardiac arrhythmia\
e. Heart failure and hospitalization within the past year\
f. Active tuberculosis\
g. Clinically evident bronchiectasis\
h. Severe emphysema requiring endobronchial interventions within 6 months prior to screening visit (Visit 1)2Patients with a history ofa. Myocardial infarction within 1 year of screening visit (Visit 1)\
b. Any malignancy unless free of disease for at least 5 years (patients with treated basal cell carcinoma or squamous cell skin cancers are allowed)\
c. Life-threatening pulmonary obstruction\
d. Chronic respiratory failure\
e. Cystic fibrosis\
f. Significant alcohol or drug abuse\
g. Thoracotomy with pulmonary resection3Patients being treated witha. Any oral and patch β-adrenergics\
b. Oral corticosteroid medication at unstable doses (i.e. less than 6 weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day\
c. Daytime oxygen therapy for more than one hour per daytime4Patients with any contraindications for exercise testing or patients who have a limitation of exercise performance as a result of factors such as arthritis in the leg, angina pectoris or claudication, or morbid obesity5Patients who have completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit 1) or patients whose pulmonary rehabilitation program is planned to be changed during the study6Patients who have taken an investigational drug within one month or six half-lives (whichever is greater) or in case the investigator drug (sub) class within washout period prior to screening visit (Visit 1)7Pregnant or nursing women or women of childbearing potential not using highly effective methods of birth control8Patients who have previously been randomized in this study or are currently participating in another study9Patients who are unable to comply with pulmonary medication restrictions prior to randomization

A patient may be withdrawn from the study before completion if the patient withdraws consent or is no longer able to participate due to medical reasons \[e.g., pregnancy, surgery, adverse events (AEs), or other diseases requiring discontinuation\], or contraindications for exercise testing have occurred. Patients may also be withdrawn for administrative reasons (continuous protocol violations or persistent non-compliance of treatment administration).

Intervention {#Sec6}
------------

Eligible patients who consent to participate in the study will be randomized in a 1:1 ratio to two sequential groups at Visit 2 and will receive one of two treatments: tiotropium/olodaterol FDC 5/5 μg inhalation solution (2.5/2.5 μg per actuation) or tiotropium 5 μg inhalation solution (2.5 μg per actuation). These medications will be provided by Nippon Boehringer Ingelheim (Tokyo, Japan) and will be administered using the RESPIMAT^®^ inhaler (Boehringer Ingelheim). The 6-week crossover treatment period does not include any washout period.

Procedure {#Sec7}
---------

Patients will be advised to self-administer the study medication at the hospital (study site) approximately at the same time at each clinic visit (Visit 2 ± 30 min and between 7:00 am and 10:00 am). Throughout the study, patients will self-administer the study medication at home, in the morning, in a seated position. Detailed written instructions and training for the use of the RESPIMAT^®^ inhaler will be given to the patient at Visit 1 and repeated at Visits 2 and 3. The investigator or qualified study personnel will observe the inhalation procedure and will reinforce a correct inhalation technique. Salbutamol is permitted as rescue medication throughout the study.

Patients will complete a patient diary confirming that study medication was taken and record both the weather conditions and the number (puffs) of rescue medication use. The study medication compliance will be emphasized to be within 80--120% compliance rate.

For performing pulmonary function tests (PFTs), unified spirometers (Flowscreen; eResearch Technology GmbH; Estenfeld, Germany) will be provided by Boehringer Ingelheim at all investigational sites throughout the study. Spirometers and their use, including daily calibration, must meet ATS/ERS criteria \[[@CR35]\]. The 6MWT will be performed according to the methodology described by ATS guidelines \[[@CR34]\], and investigators and delegated qualified personnel are required to be trained for the 6MWT procedure before recruiting patients in order to control the variability of measurement by unifying the conduct of the procedure at each center.

At Visit 1, patients will be trained on the 6MWT before the PFT is performed. At Visit 2, the 6MWT for confirming eligibility and baseline measurement will be performed before administration of the first study medication. The 6MWT will be performed at the hospital at Visit 3 and Visit 4, starting 90 min (allowance +15 min) after administration of the study medication. During the 6MWT, oxygen saturation and heart rate will be monitored using a mobile pulse oximeter. Just after the end of the 6MWT, the intensity of breathing discomfort and leg discomfort will be assessed using a modified Borg Scale.

A physical activity monitor (HJA-750C; OMRON, Kyoto, Japan) will be used for assessment of physical activity. This is a 3-axis accelerometer that is used to measure the overall movement of a patient. Patients will wear the physical activity monitor every day for 2 weeks each prior to Visit 2 for baseline assessment, and prior to Visit 3 and Visit 4 for assessment of 6-week treatment. Patients will wear the physical activity monitor all day, except during bathing or water sport activities. Investigators will request patients to avoid extreme activities (e.g., extreme exercise) which are not a part of their normal daily routine in order to facilitate proper functioning of the equipment.

Rationale for Comparator, Dose, and Duration of the Treatments {#Sec8}
--------------------------------------------------------------

Tiotropium/olodaterol is the FDC of tiotropium plus olodaterol, and we would like to know the additional effect to tiotropium, so we selected tiotropium monotherapy as comparator. The doses of both tiotropium/olodaterol FDC (5/5 µg) and tiotropium monotherapy (5 µg) were assessed in previous studies \[[@CR10]--[@CR13], [@CR15], [@CR16]\], and those doses were approved worldwide including Japan. The 6-week treatment period is the same period used in the previous studies assessing IC.

Endpoints {#Sec9}
---------

The primary endpoint is IC at rest, measured 60 min post-dose, and after 6-week treatment using FlowScreen from ERT^®^. The secondary endpoints include 6MWD (90 min post-dose), FVC (30 min post-dose), slow vital capacity (SVC) (60 min post-dose), and physical activity \[average number of steps per day (steps/day); average daily duration (min) of ≥4 metabolic equivalents (METs); average daily duration (min) of ≥3 METs; average daily duration (min) of ≥2 METs; and average daily active strength (METs min) of ≥3 METs\] after 6 weeks treatment.

Other efficacy endpoints are described in Table [2](#Tab2){ref-type="table"}. Safety assessments will include heart rate, blood pressure, and oxygen saturation in conjunction during the 6MWT, and AEs will be monitored throughout the study.Table 2Endpoints for efficacy assessment with aspect of the endpoint with data collection pointsEndpointsAspect of the assessed endpointPrimary endpoint Inspirational capacity at rest measured at 60 min post-dose, after 6 weeks treatmentLung functionSecondary endpoints 6-min walk distance \[6MWD (m)\] after 6 weeks treatmentExercise capacity Average number of steps per day (steps/day) in the 2 weeks prior to Week 6Physical activity Average daily duration (min) of ≥4 metabolic equivalents (METs) in the 2 weeks prior to Week 6 Average daily duration (min) of ≥3 METs in the 2 weeks prior to Week 6 Average daily duration (min) of ≥2 METs in the 2 weeks prior to Week 6 Average daily active strength (METs min) of ≥3 METs in the 2 weeks prior to Week 6 60 min post-dose slow vital capacity, after 6 weeks treatmentLung function 30 min post-dose FEV~1~, after 6 weeks treatment 30 min post-dose FVC, after 6 weeks treatmentFurther endpoints Intensity of breathing discomfort using modified Borg scale at 6 min during 6MWT, after 6 weeks treatment Intensity of leg discomfort using modified Borg scale at 6 min during 6MWT, after 6 weeks treatment Slope of the intensity of breathing discomfort using modified Borg scale during 6MWT, after 6 weeks treatment (intensity of breathing discomfort at the end of exercise minus intensity of breathing discomfort at rest/6MWD) Slope of the intensity of leg discomfort using modified Borg scale during 6MWT, after 6 weeks treatment (intensity of leg discomfort at the end of exercise minus intensity of leg discomfort at rest/6MWD) Symptoms measured by change in CAT, after 6 weeks treatment Change of physical activity impression, of amount and difficulties associated with physical activity in PAQ, after 6 weeks treatment SGRQ total score and symptoms, activities and impacts measured by change in SGRQ, after 6 weeks treatment Cognitive function, level of anxiety and depression to be assessed by HADS score, at baseline and after 6 weeks treatment DDR after 6 weeks treatment (DDR defined as desaturation area under the desaturation-distance curve calculated from SpO~2~/6MWD) Recovery time to saturation level (%) at rest from saturation level (%) at end of 6MWT to at rest, after 6 weeks treatment*6MWT* 6-min walk test, *CAT* COPD (chronic obstructive pulmonary disease) assessment test, *DDR* desaturation distance ratio, *FEV* ~1~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *HADS* Hospital Anxiety and Depression Scale, *PAQ* patient global physical activity rating and global rating of change, *SGRQ* St George's Respiratory Questionnaire

Data which are planned to be collected at each visit are shown in Table [3](#Tab3){ref-type="table"}.Table 3Data collected at each study visit*6-MWT* 6-min walk test,*BW* body weight,*CAT* COPD (chronic obstructive pulmonary disease) assessment test,*ECG* electrocardiogram,*EOT* end of treatment,*FEV* ~1~ forced expiratory volume in 1 s,*FVC* forced vital capacity,*HADS* Hospital Anxiety and Depression Scale,*IC* inspiratory capacity,*IRT* Interactive Response Technology,*LABA* long-acting beta2-agonist,*LAMA* long-acting muscarinic antagonist,*mMRC* modified Medical Research Council,*PAQ* patient global physical activity rating and global rating of change,*SGRQ* St George's Respiratory Questionnaire,*SVC* slow vital capacity,*T* telephone contact^a^Visit 1 may be scheduled 1--28 days after Visit 0 (depending on medication washout requirement as described in restrictions regarding concomitant treatment. Patients who are treated with LABA and LAMA should be treated at least 3 weeks with one of its' component, i.e. LABA or LAMA)^b^All patients must sign an informed consent consistent with ICH-GCP guidelines and Japanese GCP regulations prior to participation in the trial, which includes medication washout and restrictions^c^EOT examinations are completed by all patients who took at least one dose of trial medication and who discontinue early. Pulmonary Function Testing (PFT) is to be performed if possible^d^A preliminary check of in-/exclusion criteria is recommended at Visit 0 to avoid unnecessary washout procedures in non- eligible patients^e^To be performed only if relevant findings at Visit 4/EOT^f^Women of child-bearing potential: pregnancy test at Visit 1 and Visit 4/EOT^g^The patient will be instructed in the use of the RESPIMAT, but patient should not inhale from the training inhaler at Visit 2^h^Rescue medication as salbutamol is prescribed at Visit 0. Rescue medication will be collected and prescribed on subsequent Visits by investigators as needed. All rescue medication for the trial to be confirmed to be collected at Visit 4/EOT^i^Pre- and post-bronchodilator (400 μg salbutamol) \[note: reversibility is not an inclusion criterion\], Spirometry measurement; FVC and FEV1 only^j^Baseline spirometry measurement FEV1, FVC, SVC, and IC^k^Morning post-dose spirometry FEV1 and FVC: 30 min post-morning dose as starting time IC and SVC measurement: 60 min post-morning dose as starting time^l^Prior to the start of PFTs are performed^m^Modified Borg Scale for breathing and leg discomfort is administered prior to, during (every 1 min) and at the end of 6MWT. Refer to MODIFIED BORG SCALE^n^Patients should wear and measure activity monitor (3-axis accelerator) every day for 2 weeks prior to Visit 2, Visit 3 and Visit 4/EOT^o^Refer to COPD ASSESSMENT TEST™ (CAT)^p^Refer to HOSPITAL ANXIETY AND DEPRESSION SCALE^q^Site staff will telephone the patients 15 and 8 days prior to the next planned Visit and remind them to wear physical activity monitor every day. An assessment of adverse events and of concomitant therapy should be performed from the last assessment^r^Trial medication dispensed at Visit 2 should be administrated at clinic at Visit 3 and trial medication dispensed at Visit 3 should be administrated at clinic at Visit 4/EOT. Newly assigned trial medication at Visit 3 should be administered next day of Visit 3^s^Training of 6MWT^t^Training of patient diary at Visit 1. Dispense of the diary at Visit 1, Visit 2 and Visit 3. Reviewing and collection of the diary at Visit 2, Visit 3 and Visit 4/EOT

Randomization and Blinding {#Sec10}
--------------------------

Interactive Response Technology (IRT) will be used for randomization (ratio 1:1) to a treatment sequential group and for assignment of appropriate medications to eligible patients at Visit 2. Randomization will not be stratified. The IRT-assigned medication number, determined by a computer-generated random sequence, and the corresponding medication kit will be given to patients at Visit 2. Patients, investigators, and everyone involved in study conduct or analysis or with any other interest will remain blinded using this procedure.

Statistics {#Sec11}
----------

### Study Populations {#Sec12}

The randomized set will comprise all randomized patients, and the treated set (TS) will comprise patients who are documented to have taken any dose of study medication. The full analysis set (FAS), which will be used for primary endpoint analysis, will include TS patients with complete data at baseline Visit 2 and complete post-dose measurements of IC at rest. Assignment to the FAS will be done after implementation of any data handling rules, which set measurements to "missing".

The per-protocol set (PPS) will contain a subset of patients for whom serious protocol deviations have not been identified. This subset will be defined under blinded review based on the magnitude and potential impact of any serious protocol violations.

### Sample Size Calculation {#Sec13}

For the primary endpoint, the difference in IC at rest after 6 weeks treatment between the two treatment groups is estimated to be 0.1 L. To detect a difference of 0.1 L with the standard deviation of 0.41 L (based on the previously conducted replicate studies \[[@CR15]\]) in the IC at rest between the two treatments with 90% power at the 2-sided alpha of 0.05, 180 patients will be required. nQuery Advisor^®^ + nTerim v.2.0 (MOT0-1, 1-sample *t* test) was used for the sample size calculation.

### Primary and Secondary Endpoint Analyses {#Sec14}

A mixed-effects model repeated measures (MMRM; SAS procedure MIXED) approach with treatment and period as categorical fixed effects, study baseline (Visit 2) as a covariate, and patient as a random effect will be used for primary endpoint analysis (IC at rest, measured at 60 min post-dose after 6 weeks treatment). Adjusted mean values, as well as treatment contrasts, will be presented with the 95% confidence intervals and values. If the number of patients in the PPS is \<90% of the number of patients in the FAS, the primary analysis will also be performed on the PPS. These will be supportive analyses to assess the robustness of the primary analysis using the FAS. All secondary and further endpoints will be analyzed using a similar MMRM model. Descriptive statistics will be provided for each of the two treatment groups. Additionally, the analysis that the data generated during rainy weather is excluded will be performed as the sensitivity analysis to assess the impact of climate on the activity monitor \[[@CR36]\].

### Safety Analyses {#Sec15}

Safety analyses will be conducted using the TS and will be mostly descriptive in nature. No hypothesis testing is planned prospectively. AEs will be coded using the Medical Dictionary for Regulatory Activities. The number of patients with AEs during the treatment period will be summarized, and the incidence will be compared across the treatment groups. Frequency, severity, seriousness, and causal relationship of AEs will be tabulated by system organ class and preferred term.

### Data Acquisition and Handling of Missing Data {#Sec16}

Data will be collected and captured through an electronic case report form. Missing data due to worsening of COPD symptoms leading to discontinuation of study medication will be imputed by the baseline data. In other cases, missing data will not be imputed.

Discussion {#Sec17}
==========

This multicenter, randomized, double-blind, active-controlled, 2-way crossover study aims to assess the efficacy of tiotropium/olodaterol FDC compared with tiotropium monotherapy on IC as an index of lung hyperinflation in Japanese patients with COPD. The effect of these bronchodilators on exercise capacity and amount of daily physical activities will also be assessed.

This is the first clinical study assessing a LAMA + LABA combination in Japanese patients with COPD to evaluate IC as a primary endpoint and exercise capacity assessed by 6MWD and physical activity measured by 3-axis accelerometer as secondary endpoints. The Japanese COPD guidelines specifically include improvement in exercise capacity and daily physical activity as one of the six treatment goals \[[@CR5]\]; however, the evidence of exercise capacity or physical activity is limited in Japanese patients with COPD. Accordingly, evaluation of IC as an index of lung hyperinflation and its relationship with exercise capacity and physical activity in the VESUTO^®^ study will provide additional evidence for COPD management.

The 6MWD is strongly associated with pulmonary hyperinflation \[[@CR21]\], and the 6MWT will be performed to assess exercise capacity. Physical activity is potentially related to exercise capacity and is an independent prognostic factor in patients with COPD \[[@CR36]\]. Decline in physical activity is also reported in association with poor prognosis and all-cause mortality in COPD \[[@CR27], [@CR28]\]. In the VESUTO^®^ study, physical activity will be evaluated using a newly developed compact, 3-axis accelerometer. The measurements of physical activity with the 3-axis accelerometer are considered to be more objective than a questionnaire-based assessment.

Our VESUTO^®^ study has several limitations such as inclusion of Japanese patients only, refined patients than in a clinical setting with a score of ≥1 on the mMRC scale, a 6MWD \<400 m, and breathing discomfort as the modified Borg scale ≥4 measured just after the 6MWT. Additionally, since the treatment duration is only 6 weeks, assessment of the efficacy on exercise capacity and physical activity with longer treatment periods will provide valuable information on the long-term clinical benefit of bronchodilators.

Conclusions {#Sec18}
===========

In conclusion, the VESUTO^®^ study should provide further evidence of tiotropium/olodaterol FDC compared to tiotropium in lung hyperinflation, exercise capacity, and physical activity for the comprehensive treatment of Japanese patients with COPD.

Trial Status {#Sec19}
------------

Ongoing.
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